Thivanka Muthumalage1, Irfan Rahman2. 1. Department of Environmental Medicine, School of Medicine & Dentistry, University of Rochester Medical Center, Rochester, NY, USA. 2. Department of Environmental Medicine, School of Medicine & Dentistry, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: irfan_rahman@urmc.rochester.edu.
Abstract
INTRODUCTION: Cannabidiol (CBD) containing products are available in a plethora of flavors in oral, sublingual, and inhalable forms. Immunotoxicological effects of CBD containing liquids were assessed by hypothesizing that CBD regulates oxidative stress and lipopolysaccharide (LPS) induced inflammatory responses in macrophages, epithelial cells, and fibroblasts. METHODS: Epithelial cells (BEAS-2B and NHBE), macrophages (U937), and lung fibroblast cells (HFL-1) were treated with varying CBD concentrations or exposed to CBD aerosols. Generated reactive oxygen species (ROS) and inflammatory mediators were measured. Furthermore, monocytes and epithelial cells were stimulated with LPS in combination with CBD or dexamethasone to understand the anti-inflammatory effects of CBD. RESULTS: CBD showed differential effects on IL-8 and MCP-1, and acellular and cellular ROS levels. CBD significantly attenuated LPS-induced NF-κB activity, IL-8, and MCP-1 release from macrophages. Cytokine array data depicted a differential cytokine response due to CBD. Inflammatory mediators, IL-8, serpin E1, CXCL1, IL-6, MIF, IFN-γ, MCP-1, RANTES, and TNF-α were induced, whereas MCP-1/CCL2, CCL5, eotaxin, and IL-2 were reduced. CBD and dexamethasone treatments reduced the IL-8 level induced by LPS when the cells were treated individually, but showed antagonistic effects when used in combination via MCPIP (monocytic chemotactic protein-induced protein). CONCLUSION: CBD differentially regulated basal pro-inflammatory response and attenuated both LPS-induced cytokine release and NF-κB activity in monocytes, similar to dexamethasone. Thus, CBD has a differential inflammatory response and acts as an anti-inflammatory agent in pro-inflammatory conditions but acts as an antagonist with steroids, overriding the anti-inflammatory potential of steroids when used in combination.
INTRODUCTION:Cannabidiol (CBD) containing products are available in a plethora of flavors in oral, sublingual, and inhalable forms. Immunotoxicological effects of CBD containing liquids were assessed by hypothesizing that CBD regulates oxidative stress and lipopolysaccharide (LPS) induced inflammatory responses in macrophages, epithelial cells, and fibroblasts. METHODS: Epithelial cells (BEAS-2B and NHBE), macrophages (U937), and lung fibroblast cells (HFL-1) were treated with varying CBD concentrations or exposed to CBD aerosols. Generated reactive oxygen species (ROS) and inflammatory mediators were measured. Furthermore, monocytes and epithelial cells were stimulated with LPS in combination with CBD or dexamethasone to understand the anti-inflammatory effects of CBD. RESULTS:CBD showed differential effects on IL-8 and MCP-1, and acellular and cellular ROS levels. CBD significantly attenuated LPS-induced NF-κB activity, IL-8, and MCP-1 release from macrophages. Cytokine array data depicted a differential cytokine response due to CBD. Inflammatory mediators, IL-8, serpin E1, CXCL1, IL-6, MIF, IFN-γ, MCP-1, RANTES, and TNF-α were induced, whereas MCP-1/CCL2, CCL5, eotaxin, and IL-2 were reduced. CBD and dexamethasone treatments reduced the IL-8 level induced by LPS when the cells were treated individually, but showed antagonistic effects when used in combination via MCPIP (monocytic chemotactic protein-induced protein). CONCLUSION:CBD differentially regulated basal pro-inflammatory response and attenuated both LPS-induced cytokine release and NF-κB activity in monocytes, similar to dexamethasone. Thus, CBD has a differential inflammatory response and acts as an anti-inflammatory agent in pro-inflammatory conditions but acts as an antagonist with steroids, overriding the anti-inflammatory potential of steroids when used in combination.
Authors: Sara J Abdallah; Benjamin M Smith; Mark A Ware; Michelle Moore; Pei Zhi Li; Jean Bourbeau; Dennis Jensen Journal: Ann Am Thorac Soc Date: 2018-10
Authors: Timothy W Lefever; Julie A Marusich; Brian F Thomas; Daniel G Barrus; Nicholas C Peiper; Richard C Kevin; Jenny L Wiley Journal: Subst Abuse Date: 2017-04-07
Authors: Janice Gerloff; Isaac K Sundar; Robert Freter; Emily R Sekera; Alan E Friedman; Risa Robinson; Todd Pagano; Irfan Rahman Journal: Appl In Vitro Toxicol Date: 2017-03-01
Authors: Michelle R Peace; Karen E Butler; Carl E Wolf; Justin L Poklis; Alphonse Poklis Journal: Front Pharmacol Date: 2016-08-29 Impact factor: 5.810
Authors: Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey Journal: JAMA Netw Open Date: 2018-11-02
Authors: Petr Jirasek; Alexandr Jusku; Vilim Simanek; Jana Frankova; Jan Storch; Jan Vacek Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2022-03-21 Impact factor: 1.245
Authors: Chris D Verrico; Shonda Wesson; Vanaja Konduri; Colby J Hofferek; Jonathan Vazquez-Perez; Emek Blair; Kenneth Dunner; Pedram Salimpour; William K Decker; Matthew M Halpert Journal: Pain Date: 2020-09-01 Impact factor: 7.926
Authors: Pedro Augusto Lopes Tito; Túlio Cézar de Souza Bernardino; Paula Maria Quaglio Bellozi; Maria Carolina Machado da Silva; Aline Silva de Miranda; Érica Leandro Marciano Vieira; Fabrício A Moreira; András Palotás; Antônio Carlos Pinheiro de Oliveira; Helton José Reis Journal: Pharmacol Rep Date: 2021-07-03 Impact factor: 3.024